3.5.4.1: cytosine deaminase
This is an abbreviated version!
For detailed information about cytosine deaminase, go to the full flat file.
Word Map on EC 3.5.4.1
-
3.5.4.1
-
cytidine
-
deaminases
-
5-fluorocytosine
-
deamination
-
prodrugs
-
virion
-
hypermutation
-
viruses
-
5-fluorouracil
-
apolipoprotein
-
retroviruses
-
suicide
-
uracil
-
retroviral
-
apobecs
-
single-stranded
-
antiretroviral
-
polypeptide-like
-
mrna-editing
-
g-to-a
-
bystander
-
activation-induced
-
retrotransposons
-
anti-hiv-1
-
proviral
-
retroelements
-
lentiviruses
-
encapsidation
-
ganciclovir
-
deoxycytidine
-
retrotransposition
-
ssdna
-
fiv
-
samhd1
-
cullin
-
minus-strand
-
replication-competent
-
gene-directed
-
sivmac
-
medicine
-
line-1
-
hsv-tk
-
vpr
-
gdept
-
non-ltr
-
molecular biology
-
xenotropic
-
analysis
-
pharmacology
-
biotechnology
-
trim5alpha
-
diagnostics
-
proviruses
-
nickase
-
agriculture
-
single-cycle
-
elongins
- 3.5.4.1
- cytidine
- deaminases
- 5-fluorocytosine
-
deamination
-
prodrugs
- virion
-
hypermutation
- viruses
- 5-fluorouracil
-
apolipoprotein
- retroviruses
-
suicide
- uracil
-
retroviral
-
apobecs
-
single-stranded
-
antiretroviral
-
polypeptide-like
-
mrna-editing
-
g-to-a
-
bystander
-
activation-induced
-
retrotransposons
-
anti-hiv-1
-
proviral
-
retroelements
- lentiviruses
-
encapsidation
- ganciclovir
- deoxycytidine
-
retrotransposition
- ssdna
- fiv
- samhd1
-
cullin
-
minus-strand
-
replication-competent
-
gene-directed
- sivmac
- medicine
-
line-1
-
hsv-tk
- vpr
-
gdept
-
non-ltr
- molecular biology
-
xenotropic
- analysis
- pharmacology
- biotechnology
- trim5alpha
- diagnostics
- proviruses
-
nickase
- agriculture
-
single-cycle
-
elongins
Reaction
Synonyms
A3DE, APOBEC1, APOBEC3, APOBEC3G, CD, CDA, CDase, codA, CodA protein, Cytosine aminohydrolase, cytosine deaminase, cytosine deaminase I, cytosine deaminase II, cytosine deaminase P, cytosine deaminase S, cytosine deaminase Y, Fca1p, FCY1, isocytosine deaminase, yCD, Zn2+CDase
ECTree
3.5.4.1 cytosine deaminaseAdvanced search results
results (
results (Application
Application on EC 3.5.4.1 - cytosine deaminase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
agriculture
analysis
biotechnology
-
a chitosan-entrapped cytosine deaminase nanocomposite is developped. Sustained release of cytosine deaminase from the nanocomposite up to one week depicts its potential implication in prodrug inducted enzyme therapy
diagnostics
-
the enzyme, expressed by Clostridium sp., can be used for detection of Clostridia-containing tumors in humans using clostridial directed 5-fluorouracil prodrug therapy
medicine
molecular biology
pharmacology
agriculture
CodA can be used as a negative selection marker in Glycine max. Wild-type seedlings are not affected by inclusion of 5-fluorcytosine in growth media, whiule transgenic Glycine max plants expressing CodA and grown in the presence of more than 200 microg/ml 5-fluorocytosine exhibit reductions in hypocotyl and tap-root lengths, and severe suppression of lateral root development
agriculture
construction of a fusion protein of fluorocytosine deaminase FCY with the bacterial uracil phosphoribosyl transferase (UPP) gene. The recombinant protein converts the precursor 5-fluorocytosine into 5-fluorouracyl, used in the treatment of a range of cancers. The FCY-UPP gene construct acts in a cell-autonomous manner and can inactivate slow developmental processes like lateral root formation by targeting pericycle cells. The 5-fluorouracil precursor acts systemically the tissular inactivation is reversible, and can be used to synchronize plant responses or to determine cell type-specific functions during different developmental stages
agriculture
-
construction of a fusion protein of fluorocytosine deaminase FCY with the bacterial uracil phosphoribosyl transferase (UPP) gene. The recombinant protein converts the precursor 5-fluorocytosine into 5-fluorouracyl, used in the treatment of a range of cancers. The FCY-UPP gene construct acts in a cell-autonomous manner and can inactivate slow developmental processes like lateral root formation by targeting pericycle cells. The 5-fluorouracil precursor acts systemically the tissular inactivation is reversible, and can be used to synchronize plant responses or to determine cell type-specific functions during different developmental stages
-
analysis
-
crystallization strategy named microseed matrix screening, differential chelation pattern of cations by acidic surfaces of proteins within crystal lattice as a critical parameter of crystal nucleation and growth
analysis
in a selection-rooting assay CodA-expressing aerial tissues or shoot cuttings of Glycine max are inhibited for root formation in media containing 5-fluorouracil
medicine
-
oral 5-fluorocytosine in combination with selective delivery of CDase to cancerous cells by selectively introducing the bacterial CDase gene into the genome
medicine
-
treatment of cancer by infecting or implanting cytosine deaminase capsules near the tumor of a cancer patient
medicine
-
gene therapy for treatment of primary and metastatic tumors in the liver, development of gene therapy treatment for metastatic colorectal carcinoma
medicine
-
new approach to chemotherapy of cancer, using substrate 5-fluorocytosine orally and enzyme capsules implanted locally, using conversion of product 5-fluorouracil, a potent antineoplastic substance, which is strongly toxic for mammalian cells as chemotherapeutic tool against tumors, enzyme/prodrug gene therapy, artificial gene composed for metastatic colorectal carcinoma
medicine
-
facilitate pharmacological advance, possible application is transfer of FCY1 and FCA1 to mammalian cells naturally lacking enzyme activity, these genes should confer lethal sensitivity to 5-fluorocytosine
medicine
-
facilitate pharmacological advance, possible application is transfer of FCY1 and FCA1 to mammalian cells naturally lacking enzyme activity, these genes should confer lethal sensitivity to 5-fluorocytosine
medicine
-
enzyme is interesting for anticancer gene therapy since it deaminates the prodrug 5-fluorocytosine to the active drug 5-fluorouracil
medicine
enzyme is of interest both for antimicrobial drug design and for gene therapy applications against tumors
medicine
-
construction of secreted form of enzyme by fusion with pre-prosegment of human tissue plasminogen activator. Secreted enzyme temporarily spares transduced cells and enhanced accumulation of extracellular 5-fluorouracil. Tumors expressing the secreted enzyme have an improved response to 5-fluorocytosine treatment compared to tumors expressing intracellular enzyme
medicine
-
efficiency of liposome-mediated cytosine deaminase suicide gene therapy can be improved by radiation. With HR-8348 tumor xenograft model, tumor volume is inhibited by 81.5%, 48.5%, and 37.5%, in the combined enzyme/5-fluorocytosine with radiation group, enzyme/5-fluorocytosine group and radiation group, and the wet weight of tumor is decreased by 80%, 41.7%, and 37.7%, resp.
medicine
-
inhibition of tumor growth in mice treated with gene transfer of interleukin IL-12 plus enzyme/5-fluorcytosine is significantly greater than in mice treated with enzyme or IL-12 alone. Combined gene transfer increases splenic natural killer cell activity and interferon-gamma production by slenocytes and increases tumor growth inhibition and mean animal survival time
medicine
-
mutant enzyme with improved activity towards cancer prodrug 5-fluorouracil for suicide gene therapy
medicine
-
cytosine deaminase gene therapy combined with radiation treatment in breast carcinoma bone tumor, which is painful and causes osteolysis, is evaluated in a 4T1murine breast carcinoma model, overview
medicine
-
establishment of a hypoxia-dependent prodrug-activating system using the enzyme cloned into a hypoxia-targeted adenoviral vector, overview
medicine
-
hypoxia-inducible cytosine deaminase/5-fluorocytosine therapy in combination with radiation therapy shows both a pronounced bystander effect and a radiosensitizing effect under hypoxic conditions
medicine
-
the enzyme is useful in gene therapy for treatment of cancer, bladder tumor model, overview
medicine
-
the enzyme is useful in gene therapy of cancers, conjugation of poly-L-lysine to cytosine deaminase improves the efficacy of enzyme/prodrug cancer therapy, overview
medicine
-
the enzyme is useful in treatment of human ovarian cancer by genetic prodrug activation therapy, overview
medicine
-
cytosine deaminase is used in combination with 5-fluorocytosine as an enzyme-prodrug combination for targeted genetic cancer treatment
medicine
the cytosine deaminase-human mesenchymal stem cell/5-fluorocytosine system is a potential molecular chemotherapeutic tool for cancer treatment
medicine
-
the hyaluronan binding domain of tumor necrosis factor alpha-stimulated gene-6-cytosine deaminase fusion protein is an alternative to antibody-directed prodrug enzyme therapy approaches for cancer treatment
medicine
-
efficiency of gene-directed enzyme/prodrug therapy (GDEPT) based on combination of fusion yeast cytosine deaminase (yCD) and 5-fluorocytosine (5FC) on model human medullary thyroid carcinoma (MTC) cell line TT is determined. Significant bystander effect is shown in vitro and 5-fluorocytosine administration results in potent antitumor effect in vivo. In addition high efficiency of cell-mediated GDEPT is shown, when human mesenchymal stromal cells are used as delivery vehicles in direct cocultures in vitro
medicine
-
a Salmonella typhimurium strain overexpressing CodA and resistant to 5-fluorouracyl due to deletion of the Upp gene sequence, after infecting tumour cell cultures, shows increased cytotoxic and bystander effects under standard induction conditions. A PurD mutation in the producer strain controls its intracellular proliferation by the presence of adenine and avoids the intrinsic Salmonella cell death induction
medicine
-
cytosine deaminase is used in combination with 5-fluorocytosine as an enzyme-prodrug combination for targeted genetic cancer treatment
-
medicine
-
treatment of cancer by infecting or implanting cytosine deaminase capsules near the tumor of a cancer patient
-
molecular biology
structure-based, computation-guided predictive method for reversibly controlling enzyme activity using covalently attached photo-responsive azobenzene groups. Application on yeast cytosine deaminase obtains an about 3fold change in enzyme activity by the photo-controlled modulation of the enzyme's active site lid structure, while fully maintaining thermostability. Multiple cycles of switching, controllable in real time, are possible
molecular biology
-
structure-based, computation-guided predictive method for reversibly controlling enzyme activity using covalently attached photo-responsive azobenzene groups. Application on yeast cytosine deaminase obtains an about 3fold change in enzyme activity by the photo-controlled modulation of the enzyme's active site lid structure, while fully maintaining thermostability. Multiple cycles of switching, controllable in real time, are possible
-
pharmacology
-
exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy, overview
pharmacology
the recombinant fusion enzyme HSV-1TKglyCD might be useful in cancer gene therapy
pharmacology
applicability of gene-directed enzyme prodrug therapy (GDEPT), prodrug encapsulation in liposomes, liposomal 5-fluorocytosine (5-FC) achieves high local concentration for suicide therapy
pharmacology
applicability of gene-directed enzyme prodrug therapy using the capability of human adipose tissue-derived mesenchymal stem cells (AT-MSC) as cellular vehicles expressing cytosine deaminase, CDy-AT-MSC/5FC-system, analyzed in cell lines and xenografts
pharmacology
applicability of gene-directed enzyme prodrug therapy, feasibility of using magnetic resonance spectroscopy and optical imaging to measure non-invasively expression and function of cytosine deaminase in a preclinical tumor model
pharmacology
cancer chemotherapy, antibody-directed enzyme-prodrug therapy (GDEPT/ADEPT), biopanning assay
pharmacology
negative selection system for actinobacteria based on cytosine deaminase
